Credit Suisse’s Foghorn Therapeutics FHTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-1
Closed -$6 3428
2022
Q4
$6 Sell
1
-111
-99% -$837 ﹤0.01% 3797
2022
Q3
$1K Buy
112
+92
+460% +$1.18K ﹤0.01% 3846
2022
Q2
$0 Buy
+20
New +$258 ﹤0.01% 4045

Other funds holding FHTX

Credit Suisse's FHTX Position: Q1 2023 in Review

Credit Suisse sold out of Foghorn Therapeutics (FHTX) in Q1 2023, closing a stake of 1 share — an estimated $6 sold.

Credit Suisse first reported a position in FHTX in Q2 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 60 funds tracked by Wall St. Rank hold FHTX as of Q1 2023.

  • Credit Suisse reported no remaining Foghorn Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 1 Foghorn Therapeutics share in Q1 2023, an estimated $6.
  • Credit Suisse first reported a position in Foghorn Therapeutics in Q2 2022 and held it in 3 quarters.
  • Credit Suisse's Foghorn Therapeutics position peaked at $1K in Q3 2022.
  • 60 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.